Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics Inc (NQ: TPST )

1.190 -0.150 (-11.19%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 138,937
Open 1.380
Bid (Size) 1.200 (2)
Ask (Size) 1.290 (5)
Prev. Close 1.340
Today's Range 1.190 - 1.380
52wk Range 1.060 - 4.214
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tempest to Present at the Jefferies Global Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Analyst Ratings for Tempest Therapeutics
 
Via Benzinga

Performance

YTD
-2.87%
-2.87%
1 Month
-42.23%
-42.23%
3 Month
-4.80%
-4.80%
6 Month
-26.09%
-26.09%
1 Year
-57.04%
-57.04%

More News

Read More
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study: Analysts Get Bullish
Via Benzinga
Dow Surges Over 200 Points; Exxon Mobil Earnings Beat Views
Via Benzinga
Tempest Therapeutics (NASDAQ: TPST) Reports Strong Early Results From Phase 1b/2 Study of TPST-1120 in Hepatocellular Carcinoma
Via Spotlight Growth
Why First Republic Bank Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Tempest Reports Year End 2022 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.